Introduction
Germ line mutations resulting in inactivation of the mismatch repair (MMR) gene MutL homolog 1 (MLH1) are a major cause of hereditary nonpolyposis colorectal cancer (1) . Consequent loss of MMR function leads to a mutator phenotype with microsatellite instability (MSI) typifying colorectal cancer (CRC) arising in the context of hereditary nonpolyposis colorectal cancer. Deficiency of MMR is also known to play a role in the development of CRC more generally with MSI being detectable in $15% of all CRC (2) . In the majority of sporadic CRCs, MMR deficiency is thought to be an acquired event, resulting from somatic mutation or abnormal DNA methylation. It is not clear whether the events leading to loss of MMR truly occur by chance or whether some individuals are genetically susceptible to the development of this phenotype.
While the CRC risk associated with inactivating germ line MMR mutations is substantial, collectively such mutations account for only $3% of CRC incidence (1) . It is possible that common variation in the MMR genes also contributes to the inherited susceptibility to CRC, potentially having a greater impact on overall disease burden. Support for the existence of common variants influencing CRC risk has come from recent genome-wide association studies which have robustly shown that single-nucleotide polymorphisms (SNPs) localizing to 14 chromosome loci influence disease risk: 1q41, 3q26.2, 8q23.3, 8q24.21, 10p14, 11q23.1, 12q13.13, 14q22.2, 15q13.3, 16q22.1, 18q21. 1, 19q13.1, 20p12.3 and 20q13.33 (3-8) .
The MLH1-93G . A SNP (rs1800734), which maps within the MLH1 promoter, has recently been proposed as a low-penetrance allele for CRC. While an association between rs1800734 and both MLH1 silencing and MSI in CRC has been reported, no overall association between rs1800734 and CRC risk has so far been demonstrated (9) (10) (11) (12) . As the risk of CRC conferred by any common variant will be modest and the studies of rs1800734 have each been based on ,2000 CRC cases, failure to demonstrate an association with CRC risk per se may be a consequence of poor study power.
To gain further insight into the relationship between rs1800734 and CRC risk, we have conducted a large case-control study genotyping 10 409 CRC cases and 6965 controls. To further increase power to demonstrate an association between rs1800734 and CRC risk, we conducted a meta-analysis pooling our study with previously published data. Finally, we have examined the possibility of interactive effects between rs1800734 and the previously identified 14 common risk loci for CRC.
Materials and methods

Study subjects
In total, 10 637 CRC cases, aged ,80 years at diagnosis, were ascertained between March 2003 and October 2010 through the National Study of Colorectal Cancer Genetics (NSCCG) (13) (n 5 9425); the Study of the Genetic Epidemiology of Colorectal Cancer (n 5 578) and the Royal Marsden Hospital National Health Services Trust (RMHNHST) family history DNA database (n 5 634). Controls (n 5 7145) were the spouses of cancer cases and were ascertained through the NSCCG (n 5 3053); the Genetic Lung Cancer Predisposition Study (n 5 1638); the Colorectal Adenoma Gene-Environment Interactions Study (n 5 711); the Study of the Genetic Epidemiology of Colorectal Cancer (n 5 344) and the RMHNHST family history DNA database (n 5 1399). None of the controls had a personal history of malignancy at ascertainment. All subjects were British residents with self-reported European ethnicity and there were no obvious demographic differences between cases and controls. Informed written consent was obtained from all subjects, and the study was carried out with ethical review board approval [ (3) (4) (5) (6) (7) (8) . Genotyping of these SNPs and rs1800734 was conducted using KASPar competitive allelespecific PCR chemistry (KBiosciences Ltd, Hoddesdon, England, Primer sequences and conditions available on request). To monitor quality control, duplicate samples were included in assays and a subset of samples sequenced. Concordance between duplicate samples was .99%.
Tumour MSI status in CRCs was determined as described previously (13) using the mononucleotide microsatellite loci BAT25 and BAT26, which are highly sensitive MSI markers. Briefly, 10 mm sections were cut from formalinfixed paraffin-embedded CRC tumours, lightly stained with toluidine blue and regions containing at least 60% tumour microdissected. Tumour DNA was extracted using the QIAamp DNA Mini kit (Qiagen, Crawley, UK) according to the manufacturer's instructions and genotyped for the BAT25 and BAT26 loci. Samples showing more than or equal to five novel alleles, when compared with normal DNA, at either or both markers were assigned as MSI-H (corresponding to MSI-high) (14) . Tumours showing only small DNA shifts at these markers rerun directly adjacent to a normal DNA control to assign MSI status.
Statistical analysis
Statistical analyses were performed using Stata v10.0 software (StataCorporation, College Station, TX). A P-value (two sided) 0.05 was considered statistically significant. Test for Hardy-Weinberg equilibrium was performed Abbreviations: AP4, activating enhancer-binding protein 4; CI, confidence interval; CRC, colorectal cancer; LD, linkage disequilibrium; MLH1, MutL homolog 1; MMR, mismatch repair; MSI, microsatellite instability; MSI-H, microsatellite instability-high; OR, odds ratio; SNP, single-nucleotide polymorphism. among control subjects using Fisher's exact test. The CRC risk associated with the SNP was calculated by odds ratios (ORs) using unconditional logistic regression. Patterns of risk for associated SNPs were investigated by logistic regression, coding the SNP genotypes according to additive, dominant and recessive models. We then compared models by calculating the Akaike information criterion and Akaike weights for each mode of inheritance. Interaction between SNP and genotypes was evaluated by likelihood ratio tests comparing an additive model to a model with an interaction term.
The population attributable fraction ascribable to rs1800734 genotype was estimated using the formulae: (x i -1)/x i ; where
p is the population allele frequency and OR 1 and OR 2 are the ORs associated with hetero-and homozygosity, respectively.
Association between rs1800734 with tumour site (colon-ICD International Classification of Diseases 9th revision [ICD9]-153; rectal cancer -ICD9-154), Dukes stage (A þ B; C þ D), grade (poorly; moderate/well differentiated), sex, age at diagnosis ( 55, .55), family history of CRC in a first-degree relative, and MSI status was evaluated by case-only analysis.
Meta-analysis
To identify previously published studies reporting the relationship between rs1800734 genotype and CRC risk, we interrogated the electronic database PubMed (from January 1996 to the end of December 2010). The search strategy included the keywords 'rs1800734, MLH1-93G . A'. We searched for any additional studies in the bibliographies of identified publications, including previous review articles. Studies were eligible if they were based on unrelated individuals and examined the association between rs1800734 genotype and CRC risk. Only studies published as full-length articles or letters in peerreviewed journals in English were included in the analysis. Data for analyses, including study design, sample size, ethnicity, as well as allele and genotype frequencies, were extracted from the published articles and summarized in a consistent manner to aid comparison. When a study reported results on different subpopulations, we considered each subpopulation as a separate study in the meta-analysis. Raw data of genotype frequencies of rs1800734 were used for calculation of the study-specific estimates of OR and confidence interval (CI). Meta-analysis was performed using a fixed-effects model, estimating Cochran's Q statistic to test for heterogeneity and the I 2 statistic to quantify the proportion of the total variation between studies.
Bioinformatic analysis
Analysis of linkage disequilibrium (LD) was performed using the Broad Institute SNP Annotation and Proxy (SNAP) Search utilizing 1000 Genomes Project data (http://www.broadinstitute.org/mpg/snap/). The online USCS genome browser gateway (http://genome.ucsc.edu/cgi-bin/hgGateway; March 2006 NCBI36/hg18) was used to interrogate the 1 Mb region surrounding rs1800734. Transcription factor-binding prediction was performed with TFSearch (http://www.cbrc.jp/research/db/TFSEARCH.html).
Results rs1800734 genotypes were obtained for 98% of the cases (n 5 10 409) and 98% of the controls (n 5 6965) (Table I) ; hence, there was no evidence of systematic bias in genotyping between the cases and controls. Allele frequencies in controls were similar to previously published data on the Northern European population. Furthermore, there was no evidence of population stratification in controls as the genotype distribution satisfied Hardy-Weinberg equilibrium (P 5 0.40).
There was a significant overrepresentation of rs1800734 -93A genotypes in the cases compared with controls (minor allele frequencies 0.22 and 0.21, respectively) with the highest risks being conferred by AA-homozygosity; ORs 1.06 (95% CI: 1.00-1.13) and 1.10 (95% CI: 0.95-1.28) for hetero-and homozygosity, respectively (Table I) . ORs were unaffected by adjustment for age or sex. To explore for age-and sex-specific differences, we conducted a case-only analysis, using age 55 as a means of stratifying age at diagnosis of CRC. This analysis provided no statistically significant evidence that the CRC association is modified by age or gender (P . 0.05). Similarly, we found no evidence to support a relationship between rs1800734 genotype and a family history of CRC (based on having at least one first-degree relative affected with CRC).
For 3200 of the cases with known MSI status, rs1800734 genotypes were successfully generated on 3132 (98%), allowing us to calculate CRC risks stratified by MSI status. While a strong association between genotype and risk of MSI-H CRC was shown (P 5 1.45 Â 10 À4 ), there was little evidence from case-control analysis or case-only analysis to support a relationship between rs1800734 and microsatellite stable CRC (Table I) . While the pattern of risk for MSI-H CRC, of 1.21 (95% CI: 0.97-1.53; P 5 0.096) and 2.35 (95% CI: 1.60-3.45; P 5 1.49 ? 10 À5 ) associated with hetero-and homozygosity, respectively, was most parsimonious with a recessive model, a multiplicative model was equally favoured (P 5 0.66). We examined for associations of rs1800734 with age, sex, tumour site, stage, grade and family history of CRC in the MSI-H case series. rs1800734 was shown to be significantly associated with both increased age (OR: 1.66; 95% CI: 1.05-2.63; P 5 0.031) and sex (OR: 1.55; 95% CI: 1.02-2.36; P 5 0.040), being more common in females, but not with any of the other phenotypes. The association between rs1800734 and late onset MSI CRC is consistent with the SNP being a marker for an age-dependent somatic change in DNA.
Meta-analysis
To further examine the association between rs1800734 genotype and CRC risk, we conducted a meta-analysis pooling our study with previously published case-control studies. We retrieved 11 studies using our search criteria (9) (10) (11) (15) (16) (17) (18) (19) (20) (21) (22) . Three of these studies met our predetermined criteria for inclusion (9) (10) (11) . The study reported by Raptis et al. (11) provided data from the analysis of two-independent casecontrol series. There was minimal variation in the allele frequency of rs1800734 in the controls across different populations (0.19-0.23), reflective of all studies being based on Caucasian populations. Figure 1a shows a forest plot of per allele OR for CRC associated with rs1800734. All previously published studies showed some evidence for an association between genotype and CRC risk but none were statistically significant (P . 0.15). Collectively, these four studies and our analysis provided rs1800734 genotypes on a total of 14 121 CRC cases and 10 890 controls. Using these data, the summary OR was 1.06 (95% CI: 1.01-1.10; P 5 0.016), with no evidence of between study heterogeneity (P het 5 0.82; I 2 5 0%).
Two of the published studies provided rs1800734 genotype in the cases stratified by tumour MSI status (10, 11) and one by MLH1 expression (9) . Restricting analysis to either MSI-H or MLH1-deficient cancers, the pooled OR for CRC was 1.50 (95% CI: 1.34-1.67; P 5 3.43 Â 10 À12 ; P het 5 0.10, I 2 5 49%; Figure 1b) . Confining analysis to MSI-H tumours, the pooled OR was 1.47 (95% CI: 1.30-1.66, P 5 4.00 Â 10 À10 ; P het 5 0.06, I 2 5 59%).
Interaction between rs1800734 and other common risk variants
Using logistic regression analysis, we tested for an interaction between rs1800734 and each of 14 SNPs shown previously to be associated with CRC; rs6691170, rs10936599, rs16892766, rs6983267, rs10795668, rs3802842, rs11169552, rs4444235, rs4779584, rs9929218, rs4939827, rs10411210, rs961253 and rs4925386. In this dataset, each of these SNPs was significantly associated with CRC risk (Table II) . No evidence of epistasis between any of the 14 SNPs and rs1800734 was shown either in analysis of the complete dataset or when analysis was confined to MSI-H CRC (Table II) .
LD structure rs1800734 maps 93 bp upstream of the MLH1 transcription site within a 500 kb region of LD. To explore the relationship between rs1800734 
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and other common variants, we integrated 1000 genomes data for correlated SNPs mapping to this region of LD. Only two catalogued SNPs were strongly correlated with rs1800734 (i.e. r 2 . 0.5), rs749072 (r 2 5 0.78, D# 5 1.0) and rs13098279 (r 2 5 0.95, D# 5 1.0) mapping 61 and 198 kb, respectively, downstream of rs1800734, centromeric to MLH1 (Figure 2 ).
Discussion
Here, we have been able to demonstrate a statistically significant association between the MLH1-93G . A promoter polymorphism and CRC risk. On the basis of an OR of 1.06 for all CRC, the power of our study to show this relationship was $60%, stipulating a P-value of 0.05. This contrasts with previously published studies which individually have had at best $20% power, underscoring the prerequisite of large case-control studies for identifying low-risk variants, especially when associations are subtype specific. We also have been able to robustly validate the association as being restricted to MSI-H CRC. Our analyses also indicate MLH1-93G . A contributes to CRC susceptibility independent of other low-risk variants, which have been identified through recent genome-wide association studies.
Given the risk allele of MLH1-93G . A is common in the European population, the population attributable risk is compatible with this polymorphism accounting for $3% of all CRC and $11% of MSI-H CRC. On the assumption that $60% of MSI-H CRC is due to MLH1 promoter methylation (23) , this population attributable risk increases to 19%.
Studies have shown previously an association of MLH1-93G . A with increased MLH1 methylation and decreased MLH1 expression (12, 15, 18) . While we cannot exclude the possibility of the effect of rs1800734 being mediated through LD with a functional rare variant, only two highly correlated SNPs localize to the LD region to which the SNP maps, both .60 kb away from rs1800734 and not within the MLH1 gene. Moreover, several lines of evidence are compatible with MLH1-93G.A being directly functional. Notably, a recent study (24) has shown that the -93G . A substitution alters promoter function, with the -93A allele being associated with reduced activity. Furthermore, the variant appears to differentially influence nuclear protein binding (24) . 
MLH1-93G
. A localizes to an E-box consensus motif (CANNTG), to which many proteins are predicted to differentially bind -93G and -93A defined motifs. It is intriguing that activating enhancer-binding protein 4 (AP-4), which is involved in the p21/ p53 DNA damage response (25) , binds only to the -93G allele, as c-myc induces AP-4 transcription and deregulation of c-myc inhibits MMR function through interaction with MLH1 (26), thus providing a possible biological basis for the association. Additionally, AP-4 is shown to bind to such an E-box motif as part of a multiprotein complex including many DNA damage response proteins (27) . These data and recent functional studies (24) provide for a model in which AP-4 and c-myc bind adjacent binding motifs and together activate transcription of the MLH1 gene (Figure 3) . With presence of the -93A allele, a repressor protein may bind to the MLH1 promoter instead, directly inhibiting gene expression and/or leading to recruitment of epigenetic modifying factors such as DNMTs (DNA methyl transferases), causing promoter methylation and gene silencing ( Figure  3 ). While rs1800734 lies within a CpG island, it is not available for methylation and alternatively might indirectly effect methylation status of adjacent CpG residues through altered protein binding to this promoter region.
In conclusion, our data show the MLH1-93G . A polymorphism is a determinant of CRC risk. Moreover, its effect on CRC risk is confined to MSI-H tumours, thus acting as marker for a somatic event, which defines this specific CRC subtype. 
